Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glomerular therapeutics: looking back, looking forward.

R J Glassock1

  • 1UCLA School of Medicine, Los Angeles, California 92677, USA.

Heart Disease (Hagerstown, Md.)
|April 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preface.

Journal of general internal medicine·2016
Same author

Health care reforms in America: perspectives, comparisons and realities.

QJM : monthly journal of the Association of Physicians·2010
Same author

What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?

Seminars in dialysis·2000
Same author

Nephrology in the 21st century: revolutionary changes.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2000
Same author

The treatment of IgA nephropathy: status at the end of the millenium.

Journal of nephrology·2000
Same author

The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis.

Journal of the American Society of Nephrology : JASN·1999
Same journal

Ximelagatran: a new oral anticoagulant.

Heart disease (Hagerstown, Md.)·2003
Same journal

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

Heart disease (Hagerstown, Md.)·2003
Same journal

A comparison of humanistic qualities among medical students, residents, and faculty physicians in internal medicine.

Heart disease (Hagerstown, Md.)·2003
Same journal

Effect of carotid angioplasty-stenting on short-term mortality and stroke.

Heart disease (Hagerstown, Md.)·2003
Same journal

Evidence for the extrapulmonary localization of inhaled nitric oxide.

Heart disease (Hagerstown, Md.)·2003
Same journal

Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart.

Heart disease (Hagerstown, Md.)·2003
See all related articles

Glomerulonephritis treatment evolved from anecdotal use of broad agents to targeted therapies. Future advancements in genetics promise preventative and curative strategies for glomerular diseases.

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • Glomerulonephritis treatment has evolved significantly over 50 years.
  • Early therapies were largely empirical, lacking rigorous scientific validation.
  • The introduction of randomized controlled trials (RCTs) improved treatment efficacy and safety.

Purpose of the Study:

  • To review the historical progression of glomerulonephritis therapeutics.
  • To highlight the impact of evidence-based medicine on treatment strategies.
  • To forecast future directions in glomerular disease management.

Main Methods:

  • Historical review of therapeutic agents and clinical trial methodologies.
  • Analysis of treatment outcomes and shifts in clinical practice.

Related Experiment Videos

  • Exploration of emerging molecular and genetic approaches.

    • Main Results:

    • Early agents like corticosteroids and cytotoxic drugs showed variable efficacy and safety.
    • RCTs established effective and safe treatment regimens, leading to the rejection of others.
    • Selective immunosuppressants (cyclosporine, mycophenolate mofetil) improved outcomes for previously severe conditions.

    Conclusions:

    • Glomerulonephritis management has transformed from palliative to controllable.
    • Future therapies will leverage molecular genetics and pharmacogenomics for targeted, potentially curative treatments.
    • Developing and implementing novel genetic therapies will be complex but offers a paradigm shift towards prevention.